MFMichelle M. Msn Fennessy

Michelle M. Msn Fennessy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michelle M. Msn Fennessy has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Ann L. Bsn Eckhardt

    Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago (Mss Fennessy, Fink, Eckhardt, Jones, and VanderZwan, and Drs Ryan and Zerwic); Section of Cardiology, Loyola University Medical Center, Maywood, Illinois (Ms Fennessy); Carle Foundation Hospital, Urbana, Illinois (Ms Eckhardt); and Cardiac Care Unit/Surgical Heart Unit, Sherman Health, Elgin, Illinois (Ms Kruse)

    1 shared publication
  • Anne M. Fink

    Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago (Mss Fennessy, Fink, Eckhardt, Jones, and VanderZwan, and Drs Ryan and Zerwic); Section of Cardiology, Loyola University Medical Center, Maywood, Illinois (Ms Fennessy); Carle Foundation Hospital, Urbana, Illinois (Ms Eckhardt); and Cardiac Care Unit/Surgical Heart Unit, Sherman Health, Elgin, Illinois (Ms Kruse)

    1 shared publication
  • Catherine J. Ryan

    Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago (Mss Fennessy, Fink, Eckhardt, Jones, and VanderZwan, and Drs Ryan and Zerwic); Section of Cardiology, Loyola University Medical Center, Maywood, Illinois (Ms Fennessy); Carle Foundation Hospital, Urbana, Illinois (Ms Eckhardt); and Cardiac Care Unit/Surgical Heart Unit, Sherman Health, Elgin, Illinois (Ms Kruse)

    1 shared publication
  • Donna K. Msn Kruse

    Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago (Mss Fennessy, Fink, Eckhardt, Jones, and VanderZwan, and Drs Ryan and Zerwic); Section of Cardiology, Loyola University Medical Center, Maywood, Illinois (Ms Fennessy); Carle Foundation Hospital, Urbana, Illinois (Ms Eckhardt); and Cardiac Care Unit/Surgical Heart Unit, Sherman Health, Elgin, Illinois (Ms Kruse)

    1 shared publication
  • Jessica Msn Jones

    Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago (Mss Fennessy, Fink, Eckhardt, Jones, and VanderZwan, and Drs Ryan and Zerwic); Section of Cardiology, Loyola University Medical Center, Maywood, Illinois (Ms Fennessy); Carle Foundation Hospital, Urbana, Illinois (Ms Eckhardt); and Cardiac Care Unit/Surgical Heart Unit, Sherman Health, Elgin, Illinois (Ms Kruse)

    1 shared publication
  • Julie Johnson Zerwic

    Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago (Mss Fennessy, Fink, Eckhardt, Jones, and VanderZwan, and Drs Ryan and Zerwic); Section of Cardiology, Loyola University Medical Center, Maywood, Illinois (Ms Fennessy); Carle Foundation Hospital, Urbana, Illinois (Ms Eckhardt); and Cardiac Care Unit/Surgical Heart Unit, Sherman Health, Elgin, Illinois (Ms Kruse)

    1 shared publication

Latest Publications

  • Gender Differences in Fatigue Associated With Acute Myocardial Infarction

    by Michelle M. Msn Fennessy, Anne M. Fink, Ann L. Bsn Eckhardt, Jessica Msn Jones, Donna K. Msn Kruse, Kathryn J. MS VanderZwan, Catherine J. Ryan, Julie Johnson Zerwic

    INTRODUCTION: Fatigue is a symptom of acute myocardial infarction (AMI); however, few studies have characterized the fatigue associated with AMI in men and women. METHODS: The convenience sample included 88 men and 28 women admitted with a diagnosis of AMI at 6 Midwestern facilities. Data were collected upon hospital admission and 30 days after discharge. A total of 37 men and 10 women responded to the 30-day questionnaires. The Profile of Mood States Fatigue (POMS-F) subscale was used to measure fatigue and the Depression-Dejection subscale to measure depressed mood. RESULTS: At baseline, significant gender differences were found, with women more likely to have higher POMS-F scores (15.80, SD = 7.33) than men (11.19, SD = 7.04, P = .004). Significant gender differences were also found at 30 days (t = 2.40, df = 45, P = .02). POMS-F scores for women were higher at baseline, with decreased fatigue levels 30 days after discharge (t = 5.36, df = 9, P ≤ .05). No differences were found in POMS-F scores for men (t = 1.26, df = 36, P = .213) between baseline and 30 days after discharge. Fatigue was associated with depressed mood and gender at baseline (R2 = 0.48, P < .05) and 30 days after discharge (R2 = 0.308, P < .05). CONCLUSIONS: In this sample, fatigue at baseline and at 30 days after discharge was associated with gender and depressed mood. Women reported high levels of fatigue with AMI and lower fatigue after discharge. Men reported moderate to high fatigue levels, which did not change over time. Further research is needed to discern fatigue patterns before and after AMI.


  • Clinical Benefits of Drug-Eluting Stents

    by Michelle M. Fennessy, William B. Borden

    Drug-eluting stents have revolutionized interventional cardiology by incorporating drug and device therapy to reduce rates of restenosis. Early trials have addressed the safety and efficacy of drug-eluting stents. Recent studies have evaluated the use of drug-eluting stents in high-risk populations that were not initially randomized in the early trials. These stents have shown promising outcomes in diabetes, in-stent restenosis, and multivessel disease. The clinical benefits of these stents have been systematically quantified across multiple trials; however, there is a growing debate regarding restenosis and late-stent thrombosis after implantation. Given the expanding indications for drug-eluting stents, the American Heart Association identified it as one of the Top 10 Research Advances for 2005. The purpose of this article is to summarize the current debate surrounding late-stent thrombosis, examine the evidence from leading stent trials, and outline the clinical benefits of drug-eluting stents.